In this video, Dr. Sarah Telaney, a breast medical oncologist at Dana-Farber Cancer Institute, shares key takeaways from ESMO 2024, highlighting three impactful studies in breast oncology. She discusses the promising outcomes of preoperative pembrolizumab for early-stage triple-negative breast cancer, the significant efficacy of trastuzumab deruxtecan (T-DXd) in patients with metastatic HER2-positive disease and brain metastases, and the recently FDA-approved ribociclib for early-stage hormone receptor-positive breast cancer. Dr. Telaney emphasizes the exciting pace of drug development and its potential to improve patient care.

The five-day Menopause Society (formerly the North American Menopause Society) 2024 annual meeting took place Sept. 10 to 14 at the Hyatt Regency in Chicago. The agenda was jam-packed with the latest research in understanding and treating menopausal symptoms, with a special focus on artificial intelligence in the women’s health landscape.

Click the link above to find our postconference wrap-up report.

Taking place at the Hyatt Regency in Chicago, The Menopause Society (formerly North American Menopause Society) is holding its 2024 annual meeting, which spans five days. Attendees are finding it filled with the latest research on understanding and treating menopausal symptoms.

This year’s meeting theme, Humanizing Artificial Intelligence to Improve Midlife Women’s Health, includes actionable advice on the use of artificial intelligence (AI) in clinical practice as well as updates on how AI relates to menopause and midlife women’s health and how future applications may be able to personalize hormone replacement therapy.

Click the link above to find out more about the highlights and programs covered during this years Menopause Society Annual Meeting.